LEADER 02172nam  2200421z- 450 
001 9910220055103321
005 20231214133429.0
035   $a(CKB)3800000000216227
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/62680
035   $a(EXLCZ)993800000000216227
100   $a20202102d2016      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aWhy vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens
210   $cFrontiers Media SA$d2016
215   $a1 electronic resource (157 p.)
225 1 $aFrontiers Research Topics
311   $a2-88919-966-5 
330   $aDespite continuous progress in the development of anti-viral and anti-bacterial/parasite drugs, the high cost of medicines and the potential for re-infection, especially in high risk groups, suggest that protective vaccines to some of the most dangerous persistent infections are still highly desirable. There are no vaccines available for HIV, HCV and Malaria, and all attempts to make a broadly effective vaccine have failed so far. In this Research Topic we look into why vaccines have failed over the years, and what we have learn from these attempts. Rather than only showing positive results, this issue aims to reflect on failed efforts in vaccine development. Coming to understand our limitations will have theoretical and practical implications for the future development of vaccines to these major global disease burdens.
610   $ainfluenza
610   $aHIV
610   $aMalaria
610   $aInfectious Disease
610   $aGenetics
610   $aVaccine
610   $aHCV
610   $aimmunology
700   $aMagdalena Plebanski$4auth$01296310
702   $aEric J. Gowans$4auth
702   $aPeter Smooker$4auth
702   $aShuo Li$4auth
906   $aBOOK
912   $a9910220055103321
996   $aWhy vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens$93023985
997   $aUNINA